Abstract:Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated efficacy in treating relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). However, some patients experience relapse due to a high tumor burden prior to CAR T-cell therapy, which poses a significant challenge for disease control. Moreover, patients who have achieved complete remission through salvage chemotherapy often fail to meet the inclusion criteria for clinical trials of CAR-T therapy, as well as the indications for commercial CAR-T therapy.Currently, there are very few clinical trials investigating consolidation with CAR T-cell therapy for patients with R/R B-NHL in complete remission (CR). Aims: This study aims to assess the safety and long-term effectiveness of CAR-T therapy as consolidation therapy for R/R B-NHL patients who achieve CR after salvage therapy. Methods: From June 2019 to June 2022,36 patients with relapsed/refractory B-NHL who has achieved complete remission after salvage chemotherapy were included in the study.Patients diagnosed with BL,HGBL,PCNSL,PMBL were combined with autologous stem cell transplantation(ASCT).Diagnoses included DLBCL NOS(n=18),PCNSL(n=6),HGBL(n=2),BL(n=2),Richter(n=1),FL(n=1),PMBCL(n=4) and SCNSL(n=2).Median age was 51 years (range 21-76).75% (27/36) received ≧3 lines of prior treatment.19% (7/36) patients had experienced failure of prior ASCT.52% (12/23) cases were found to have TP53 mutations. Results: After a median follow-up of 15.32 months(range 4.9-43.4), 91.67% (33/36) of patients continuing to have a complete response and 97% (35/36) survival. One-year progression free survival and overall survival were 89% and 95%, respectively.15 patients received CAR T-cells infusion alone and 21 patients received CAR T-cells combined with ASCT.The median dose of CAR-T cell infusion was 1.9 x 10^6/kg and it rapidly expanded after infusion in 33 patients.Median peak expansion occured on day 11 which is 3.365*10^7/L(PB) as measured by Flow Cytometry and 5032 copy/reaction system by quantitative PCR.69.4% (24/36) experienced cytokine release syndrome(CRS) and 5.6%(2/36)was ≥grade 3 CRS and no neurological events. Steroids were used by 22.2% (8/36) of patients at a median dose of 18 mg, and 2.7% (1/36) required tocilizumab for CRS management. 27.8%(10/36) experienced pulmonary infections and intestinal infections were observed in 19.4%(7/36).The group that received CAR-T therapy combined with ASCT achieved neutrophil and platelet engraftment in all cases on median days 12 (range 8-33) and 13 (range 5-63), respectively. Summary/Conclusion: CAR-T combined with or without ASCT as the consolidation therapy is safe for patients with agressive R/R B-NHL who has achieved complete remission after salvage chemotherapy.This approach significantly reduces the relapse rate and mortality, and prolongs progression-free survival. Combining CAR-T therapy with ASCT does not increase the risk of cytokine release syndrome or infection. Furthermore, CAR-T cell expansion does not appear to be affected by tumor burden.Nonetheless, larger patient cohorts and longer follow-up periods are necessary to fully evaluate the clinical application of this approach in the future.Keywords: Autologous hematopoietic stem cell transplantation, Consolidation, CAR-T

Efifcacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma

Consolidation Therapy with Autologous Stem Cell Transplantation after Remission of Induction Chemotherapy Prolongs the Survival of Patients with Peripheral T-cell Lymphoma

[Clinical Efficacy of Autologous Hematopoietic Stem Cell Transplantation Using Tumor-ablative Conditioning Regimen for Patients with Refractory/Relapsed Non-Hodgkin's Lymphoma].

Efficacy of autologous hematopoietic stem cell transplantation in.treatment of relapsed and/or refractory classical Hodgkin lymphoma

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used As Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission.

[Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].

Comparison of the Efficiency of CHOP-based Regimen with or Without High Dose Consolidation Treatment Combined with Hematopoietic Stem Cell Transplantation in 63 Lymphoblastic Lymphoma Patients

The preliminary results of treatment ofadvanced and recurrent malignant lymphoma by beac regimen supported with autologous hematopoietic stem cells transplantation

Treatment of Relapsed/refractory Non-Hodgkin Lymphoma by Autologous Hemotopoietic Stem-Cell Transplantation with BEAM As Conditioning Regimen

High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China

Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation

Effect Comparison Between Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Patients of Aggressive Non-Hodgkin′s Lymphoma

Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL

[Clinical Efficiency of Rituximab Combined with Autologous Hematopoietic Blood Stem Cell Transplantation for Treatment of CD20+ B non.Hodgkin Lymphoma].

Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk Stage III to IV Hodgkin Lymphoma: a Multicenter Retrospective Cohort Study.

Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-cell therapy on the survival of patients with relapsed or refractory multiple myeloma

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

The Superiority of Haploidentical Related Stem Cell Transplantation over Chemotherapy Alone As Postremission Treatment for Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in First Complete Remission.

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy